Diligence memo · auto-generated · as of July 3, 2026
Trio Pharmaceuticals, Inc.
Trio Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Trio Pharmaceuticals, Inc. operates in Biotech / Pharma, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Trio Pharmaceuticals, Inc. has raised $1.9M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.9M on 2022-11-01.
Most recent recorded round closed around 2022-11-01.
Valuation (modeled)modeled
Provath models Trio Pharmaceuticals, Inc. at approximately $22M (range $1.4M–$94M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.31× the median modeled value of Seed Biotech / Pharma companies in 2022–2024 (14 peers) — value vs value, same stage and era. Within the normal band (131% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.7 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 36% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 45% of those peers.
Closest niche peers: Outer Biosciences, LLC, Slate Bio, Inc., CASS Pharmaceuticals, Inc., FOOP Organic Biosciences, Inc., Aruka Bio, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.